AC
RKDA icon

Armistice Capital’s Arcadia Biosciences RKDA Stock Holding History

Armistice Capital’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-159,390
Closed -$220K – 406
2026
Q1 		$220K Buy
+159,390
New +$312K ﹤0.01% 222
2023
Q2 		– Sell
-82,500
Closed -$616K – 266
2023
Q1 		$616K Buy
82,500
+69,063
+514% +$733K 0.01% 152
2022
Q4 		$146K Sell
13,437
-26,849
-67% -$382K ﹤0.01% 157
2022
Q3 		$850K Buy
+40,286
New +$1.37M 0.01% 142

Other funds holding RKDA

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Armistice Capital's RKDA Position: Q2 2026 in Review

Armistice Capital sold out of Arcadia Biosciences (RKDA) in Q2 2026, closing a stake of 159,390 shares — an estimated $220K sold.

Armistice Capital first reported a position in RKDA in Q3 2022 and held it in 4 quarters. The position peaked at $850K in Q3 2022. 17 funds tracked by Wall St. Rank hold RKDA as of Q2 2026.

  • Armistice Capital reported no remaining Arcadia Biosciences position as of Q2 2026 after selling out during the quarter.
  • Armistice Capital sold 159,390 Arcadia Biosciences shares in Q2 2026, an estimated $220K.
  • Armistice Capital first reported a position in Arcadia Biosciences in Q3 2022 and held it in 4 quarters.
  • Armistice Capital's Arcadia Biosciences position peaked at $850K in Q3 2022.
  • 17 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.